{"id":"W4230409425","doi":"10.1200/jco.2019.37.7_suppl.tps499","title":"A phase III, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Durvalumab; Tremelimumab; Medicine; Oncology; Internal medicine; Gemcitabine; Carboplatin; Chemotherapy; Cetuximab; Response Evaluation Criteria in Solid Tumors; Cisplatin; Immunotherapy; Cancer; Ipilimumab; Phases of clinical research; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004073311,0.003081651,0.002947171,0.000674669,0.0006439384,0.001579138,0.001762057,0.00256241,0.006157542],"category_scores_gemma":[0.001904293,0.001063335,0.00244615,0.0006036472,0.002368693,0.002104045,0.0007720161,0.004550125,0.001813734],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001666021,"about_ca_system_score_gemma":0.002622389,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001287078,"about_ca_topic_score_gemma":0.002781987,"domain_scores_codex":[0.9988955,0.0006272147,0.00003417871,0.0001943719,0.00006704999,0.0001816676],"domain_scores_gemma":[0.9981167,0.0003210556,0.0003983783,0.0001460298,0.0001173572,0.000900569],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9415898,0.03387005,0.001631646,0.0004067947,0.0009574944,0.00005070087,0.0001248023,0.000679592,0.005339989,0.0001512935,0.001957149,0.01324069],"study_design_scores_gemma":[0.8696586,0.1263573,0.001909239,0.0000151521,0.0002686271,0.00004514578,0.00002889148,0.0003631397,0.0005021384,0.0001222101,0.0007120417,0.00001744364],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9800933,0.002176056,0.0012867,0.001328618,0.0004709811,0.009240193,0.002822106,0.0002840378,0.002298088],"genre_scores_gemma":[0.9681466,0.001832249,0.004790831,0.003453524,0.0005327434,0.01216616,0.00452311,0.0001086541,0.004445966],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006157542,"threshold_uncertainty_score":0.02154195,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04578222381154633,"score_gpt":0.4217674698569827,"score_spread":0.3759852460454363,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}